Evidence map›Paper›PMID 41381212›Full record

ArticleRMD open2025

Circulating monocytes from systemic sclerosis patients with progressive interstitial lung disease preferentially express M2 phenotype markers: in vitro and ex vivo study.

Vanessa Smith, Stefano Soldano, Rosanna Campitiello, Paola Montagna, Andrea Cere, Elvis Hysa, Tamara Vojinovic, Carmen Pizzorni, Sabrina Paolino, Alberto Sulli and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RMD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Vanessa Smith *Department of Rheumatology and Internal Medicine, University Hospital Ghent, Ghent, Flanders, Belgium.ORCID http://orcid.org/0000-0001-6271-7945
Stefano Soldano *Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialities (Di.M.I.), University of Genoa, Genoa, Liguria, Italy.
Rosanna Campitiello *Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialities (Di.M.I.), University of Genoa, Genoa, Liguria, Italy.
Paola MontagnaLaboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialities (Di.M.I.), University of Genoa, Genoa, Liguria, Italy.
Andrea CereLaboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialities (Di.M.I.), University of Genoa, Genoa, Liguria, Italy.
Elvis HysaLaboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialities (Di.M.I.), University of Genoa, Genoa, Liguria, Italy.
Tamara VojinovicLaboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialities (Di.M.I.), University of Genoa, Genoa, Liguria, Italy.
Carmen PizzorniLaboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialities (Di.M.I.), University of Genoa, Genoa, Liguria, Italy.
Sabrina PaolinoLaboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialities (Di.M.I.), University of Genoa, Genoa, Liguria, Italy.
Alberto SulliLaboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialities (Di.M.I.), University of Genoa, Genoa, Liguria, Italy.
Emanuele Gotelli *Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialities (Di.M.I.), University of Genoa, Genoa, Liguria, Italy.ORCID http://orcid.org/0000-0002-4732-0306
Maurizio Cutolo *Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialities (Di.M.I.), University of Genoa, Genoa, Liguria, Italy mcutolo@unige.it.ORCID http://orcid.org/0000-0002-5396-0932

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo characterise phenotype and functional profibrotic M2 markers in circulating monocytes and cultured monocyte-derived macrophages (MDMs) from systemic sclerosis (SSc) patients (pts) with progressive interstitial lung disease (ILD) (prog-ILD), non-progressive ILD (no-prog-ILD) and without ILD (no-ILD).

methodsFifty-five SSc pts and 20 age-matched healthy controls were evaluated. In 36 SSc pts, circulating monocytes expressing toll-like receptor-4 (TLR4, M1 marker) and M2 phenotype markers (CD204, CD206, CD163) were detected by flow cytometry. Moreover, MDMs of 29 SSc pts were analysed by quantitative real-time PCR and Western blotting for gene expression and protein synthesis with regard to the production of profibrotic mediators: transforming growth factor-ß1 (TGFß1), Mer tyrosine kinase receptor (MerTK) and arginase-1 (ARG1). Interleukin-6 and 4 (IL6, IL4), as well as C-C motif chemokine ligand 2 and 18 (CCL2/MCP1 and CCL18) from culture medium, were evaluated by enzyme-linked immunosorbent assay (ELISA).

resultsProg-ILD SSc pts showed a higher percentage of TLR4

conclusionsCultured MDMs from circulating monocytes in SSc pts with prog-ILD show markedly increased profibrotic biomarkers and mediator expression, indicating an enhanced fibrotic phenotype compared to non-prog and no-ILD SSc pts.

Indexed as

BiomarkersLung Diseases, InterstitialMonocytesScleroderma, SystemicAdultAgedCase-Control StudiesCells, Culturedc-Mer Tyrosine KinaseCytokinesDisease ProgressionFemaleHumansMacrophagesMaleMiddle AgedBiomarkersc-Mer Tyrosine KinaseCytokinesToll-Like Receptor 4Autoimmune DiseasesConnective Tissue DiseasesLung Diseases, InterstitialPulmonary FibrosisScleroderma, Systemic

Identifiers

PMID41381212
PMCPMC12706102

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.